KR102437662B1 - 신규한 알파-1-마이크로글로불린 유래 단백질 및 이의 용도 - Google Patents

신규한 알파-1-마이크로글로불린 유래 단백질 및 이의 용도 Download PDF

Info

Publication number
KR102437662B1
KR102437662B1 KR1020187029939A KR20187029939A KR102437662B1 KR 102437662 B1 KR102437662 B1 KR 102437662B1 KR 1020187029939 A KR1020187029939 A KR 1020187029939A KR 20187029939 A KR20187029939 A KR 20187029939A KR 102437662 B1 KR102437662 B1 KR 102437662B1
Authority
KR
South Korea
Prior art keywords
glu
thr
gly
lys
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187029939A
Other languages
English (en)
Korean (ko)
Other versions
KR20180127411A (ko
Inventor
레나 베스터 로젠외프
애널리 애드스트룀 호겔발
보 오케스트룀
Original Assignee
가드 테라퓨틱스 인터내셔널 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가드 테라퓨틱스 인터내셔널 에이비 filed Critical 가드 테라퓨틱스 인터내셔널 에이비
Publication of KR20180127411A publication Critical patent/KR20180127411A/ko
Application granted granted Critical
Publication of KR102437662B1 publication Critical patent/KR102437662B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
KR1020187029939A 2016-03-18 2017-03-17 신규한 알파-1-마이크로글로불린 유래 단백질 및 이의 용도 Active KR102437662B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670158 2016-03-18
DKPA201670158 2016-03-18
PCT/EP2017/056436 WO2017158181A1 (en) 2016-03-18 2017-03-17 Novel alpha-1-microglobulin derived proteins and their use

Publications (2)

Publication Number Publication Date
KR20180127411A KR20180127411A (ko) 2018-11-28
KR102437662B1 true KR102437662B1 (ko) 2022-08-29

Family

ID=56080208

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029939A Active KR102437662B1 (ko) 2016-03-18 2017-03-17 신규한 알파-1-마이크로글로불린 유래 단백질 및 이의 용도

Country Status (15)

Country Link
US (1) US10981963B2 (enExample)
EP (1) EP3430032B1 (enExample)
JP (1) JP6976579B2 (enExample)
KR (1) KR102437662B1 (enExample)
CN (1) CN108779157B (enExample)
AU (1) AU2017235608B2 (enExample)
BR (1) BR112018068522A2 (enExample)
CA (1) CA3017836A1 (enExample)
EA (1) EA039776B1 (enExample)
ES (1) ES2896734T3 (enExample)
MX (1) MX2018011193A (enExample)
NZ (1) NZ746677A (enExample)
SG (1) SG11201807352XA (enExample)
WO (1) WO2017158181A1 (enExample)
ZA (1) ZA201805797B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019086569A1 (en) * 2017-11-03 2019-05-09 A1M Pharma Ab Use of alpha-1-microglobulin for protection of bone marrow cells
AU2024219294A1 (en) 2023-02-08 2025-07-10 Guard Therapeutics International AB Alpha-1-microglobulin derived peptide fragments and uses thereof
US12227343B2 (en) * 2023-03-17 2025-02-18 Blue Buffalo Enterpises, Inc. Retail ready opening feature for e-commerce carton

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505154A (ja) * 2008-07-18 2012-03-01 アケルストロム，ボー ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
JP2015533790A (ja) 2012-09-05 2015-11-26 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ ミトコンドリア関連疾患の治療に使用するためのα−１−ミクログロブリン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758554B2 (en) * 2012-01-31 2017-09-12 Technische Universitaet Muenchen Muteins of α1m lipocalin and method of production therefor
US8727893B2 (en) * 2012-09-21 2014-05-20 Beintoo, S.P.A. Interactive experience fully contained within an expandable embedded unit
US10226570B2 (en) * 2017-03-10 2019-03-12 Seton Healthcare Family Apparatus and method for temporarily securing a movable accessory device relative to a movable patient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505154A (ja) * 2008-07-18 2012-03-01 アケルストロム，ボー ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
JP2015533790A (ja) 2012-09-05 2015-11-26 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ ミトコンドリア関連疾患の治療に使用するためのα−１−ミクログロブリン

Also Published As

Publication number Publication date
JP2019519466A (ja) 2019-07-11
MX2018011193A (es) 2019-03-28
WO2017158181A1 (en) 2017-09-21
ES2896734T3 (es) 2022-02-25
EA201892085A1 (ru) 2019-02-28
EP3430032A1 (en) 2019-01-23
CN108779157A (zh) 2018-11-09
BR112018068522A2 (pt) 2019-01-22
NZ746677A (en) 2023-02-24
US10981963B2 (en) 2021-04-20
KR20180127411A (ko) 2018-11-28
ZA201805797B (en) 2022-03-30
SG11201807352XA (en) 2018-09-27
JP6976579B2 (ja) 2021-12-08
CA3017836A1 (en) 2017-09-21
EA039776B1 (ru) 2022-03-11
CN108779157B (zh) 2022-12-30
US20190161524A1 (en) 2019-05-30
EP3430032B1 (en) 2021-09-01
AU2017235608A1 (en) 2018-10-18
AU2017235608B2 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
CA2862516C (en) Compositions and methods of use for treating metabolic disorders
US20220370560A1 (en) Ptd-smad7 therapeutics
CN108779157B (zh) 新α-1-微球蛋白衍生蛋白及其应用
KR20220125289A (ko) Fgf-21 접합체 제제
KR20080106450A (ko) 단백질, 핵산 및 약제
AU2003234066B2 (en) Muteins of placental growth factor type 1, preparation method and application thereof
KR20150140686A (ko) 신증후군 및 관련 병태의 치료 방법
US10385113B2 (en) Engineered FGF compositions and methods of use thereof
CN113121668B (zh) PEG修饰的可抑制gp96的多肽、其制备方法及用途
CN120712100A (zh) α-1-微球蛋白衍生的肽片段及其用途
EP2742947B1 (en) Bilirubin excretion enhancer
WO2025172720A1 (en) Fragment of complement factor h related protein 5 which restores complement regulation
WO2015103782A1 (en) Fgf21 mutant and conjugate thereof
JPH1080281A (ja) 新規蛋白質及びその製造方法
NZ615495A (en) Anti-inflammatory proteins and peptides and methods of preparation and use thereof
HK1079549B (en) Muteins of placental growth factor type 1, preparation method and applicaiton thereof

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000